SOFTMEDX-NEW (00648) announced its interim results for 2025, reporting revenue of HK$35.771 million, representing a 16.5% increase year-on-year. Profit attributable to shareholders reached HK$3.353 million, compared to a loss attributable to shareholders of HK$6.093 million in the same period last year, successfully turning from loss to profit. Basic earnings per share stood at 1 HK cent. According to the announcement, the revenue growth was primarily attributed to the group's continuous efforts to expand product sources and broaden its product portfolio.